drugset / Trial / NCT00367081

Treatment of Cerebral Toxoplasmosis in HIV/AIDS

NCT00367081

RandomizedParallel-groupSingle-blindTreatment

Summary

Neurological manifestations of Cerebral toxoplasmosis or Toxoplasmic encephalitis (TE) in most advance stage HIV infected patients composed of fever, headache, alteration of consciousness with focal neurological signs/symptoms such as include hemiparesis, cranial nerve palsies, and ataxia. Generalised convulsions, in ¾ of patients. Moreover meningeal irritation sign or herniation sign may be presented as life threatening condition

Timeline

Start
2003-05
Primary completion
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sulfadiazine Unknown 4 g
Subject Sulfamethoxazole Small molecule 50 mg/kg Intravenous
Subject Trimethoprim Small molecule 10 mg/kg Intravenous
Subject pyrimethamine Small molecule 50 mg
Subject pyrimethamine Small molecule 100 mg
Background leucoverin Unknown 25 mg